Empagliflozin reduced ventricular arrhythmia episodes (18% vs 28%) and appropriate ICD shocks (14% vs 21%) in heart failure patients with reduced ejection fraction.
Systematic Review (n=463)
Does empagliflozin reduce ventricular arrhythmias and ICD therapies in heart failure patients with an implantable cardioverter-defibrillator?
Empagliflozin may provide anti-arrhythmic benefits by significantly reducing ventricular arrhythmias and the need for ICD therapies in patients with HFrEF.
Absolute Event Rate: 18% vs 28%
Abstract Background a 22% reduction in late gadolinium enhancement on cardiac MRI, and lower serum biomarkers of myocardial fibrosis, including galectin-3 and ST2 as reported by EMPEROR-Preserved trial. Conclusions Empagliflozin is associated with a lower incidence of ventricular arrhythmias and ICD interventions in HF patients, suggesting a potential anti-arrhythmic benefit. Larger, long-term trials are needed to confirm these findings and elucidate underlying mechanisms.
Hunjul et al. (Sat,) conducted a systematic review in Heart failure with reduced ejection fraction (HFrEF) and an implantable cardioverter-defibrillator (n=463). Empagliflozin vs. Control was evaluated on Ventricular arrhythmia episodes. Empagliflozin reduced ventricular arrhythmia episodes (18% vs 28%) and appropriate ICD shocks (14% vs 21%) in heart failure patients with reduced ejection fraction.